- The
company believes that its total revenue will more than double in 2020, led
by commercialization of its revolutionary CBD oil nanoemulsification
system
- PBIO’s
BaroShear K45, based on the company’s proprietary Ultra Shear Technology
(UST) platform, revolutionizes the manufacture of water-soluble,
long-term, stable, highly absorbable, nanoemulsified CBD oil
- The
worldwide CBD market is expected to reach $20 billion in sales by 2024,
with competition ramping up as CBD manufacturers seek new ways to stand
out
- PBIO
has announced three pre-sales of its BaroShear K45 nanoemulsification
system for making water-soluble CBD Oil
- Progress
continues on the build-out of its GMP-compliant manufacturing laboratory
to showcase the BaroShear K45 and its industrial scale, high volume
UST-based nanoemulsification systems (release date to be determined)
Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based technology and
products to the worldwide life sciences and other industries, expects its total
revenues to more than double in 2020 following the successful launch of its
revolutionary CBD (cannabidiol) processing system – the BaroShear K45. This
novel processing system creates a water-soluble CBD oil that disperses
instantly in liquid, providing enhanced quality and bio-absorption (http://ibn.fm/PSUr8).
Development of the BaroShear K45 system began following the
company’s in-depth analysis of the CBD market, which showed a common, yet
critical production issue facing CBD manufacturers – the poor water solubility
of today’s oil-based CBD products means that the beneficial properties of CBD
are inadequately available for absorption in the body.
“After much diligence and analysis, we concluded that we
have the expertise and experience to successfully address this critical issue,”
Richard T. Schumacher, president and CEO of PBIO, stated in an August 2019
shareholder report (http://ibn.fm/Ym0dG).
“Consequently, we pulled significant hours away from many of our staff over the
past few months and had them focus on the development of an instrument system –
based on our patented UST platform – that would increase the water-solubility,
and thus the absorption, of CBD Oil. We succeeded; the result of that success
is the BaroShear K45 processing system.”
The collective market for CBD sales in the U.S. is expected
to exceed $20 billion by 2024, according to a new report from BDS Analytics and
Arcview Market Research (http://ibn.fm/RJsFW).
The forecast includes products sold through licensed dispensaries and general
retail outlets such as grocery stores, mass merchants and pharmacies. Standing
out from the crowded field of competitors will be essential for any business
pursuing the spotlight in a rapidly expanding CBD marketplace.
“To survive, companies will need to differentiate themselves
from the competition by delivering the highest quality products possible,”
Schumacher added. “Such products would undoubtedly need to have high
water-solubility, absorption, and bioavailability, along with long shelf-life
and a minimal amount of added chemicals. This is exactly what we intend to
deliver.”
PBIO announced the initial sale of the BaroShear K45
processing system to its first customer, Nano CBD Cosmetics LLC, in an earlier
news release (http://ibn.fm/XSn75).
Nano CBD Cosmetics founder and CEO Christopher Holden expressed excitement with
his company’s purchase.
“We are thrilled to be the first purchaser of the BaroShear
K45 system,” Holden stated in the release. “This groundbreaking technology will
enable companies producing nano-scale CBD emulsion products to meet the
ever-increasing demand for CBD nanoemulsion products. In fact, our own nano-CBD
products are currently selling faster than we can produce them. However, with
PBIO’s cutting-edge technology, we expect to increase our nano-emulsified,
water-soluble CBD production capacity to many multiples of what it is today…
and that is huge.”
Following the announcement of its initial pre-sale, PBIO has
continued to pre-sell additional, limited quantities of the BaroShear K45. The
company recently announced two additional pre-sales of the K45 system (http://ibn.fm/ExADD) – one to
NanoPeak Solutions Inc., a private company located in Vancouver, British
Columbia, and the second to a private company in Las Vegas, Nevada. This leaves
just nine remaining systems available for the PBIO pre-sell program. Units sold
over the coming weeks are on track to be delivered and installed in the first
half of 2020.
“We believe that such sales will have a significant impact
on 2020 total revenue, potentially resulting in more than twice the total
revenue of 2019,” Schumacher stated in a news release. “We further believe that
revenue from our BaroFold platform contract services will continue to increase,
and that the decline in PCT platform instrument sales observed over the past
two quarters (caused in part by our focus on the development of the BaroShear
K45) will end, and that we will see an increase in PCT product sales over the
second half of 2019, and beyond.”
Two short videos released by PBIO (http://ibn.fm/WZy4P and http://ibn.fm/9EqfO), showing
how its patented UST platform is able to process CBD plant oil into a
water-soluble nanoemulsion, give a quick lesson in PBIO’s proprietary
technology.
For more information, visit the company’s website at www.PressureBioSciences.com
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
